CLS: Rights issue outcome and focus on neurosurgery - Redeye

Redeye provides an update as we resume our coverage after CLS’ rights issue. We adjust our model accordingly to the rights issue outcome, make estimate changes following the company’s increased focus on neurosurgery, and comment on CLS’ Q1 report. As a result, we provide an updated diluted fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1017869/cls-rights-issue-outcome-and-focus-on-neurosurgery?utm_source=finwire&utm_medium=RSS